Dexart


Combined with:

Kytril

Indications and Reactions:

Role Indications Reactions
Secondary
Prophylaxis 42.9%
Drug Use For Unknown Indication 10.2%
Breast Cancer 8.6%
Multiple Myeloma 6.3%
Rectal Cancer Metastatic 5.3%
Refractory Cancer 3.3%
Premedication 2.9%
Breast Cancer Recurrent 2.7%
Prophylaxis Of Nausea And Vomiting 2.7%
Acute Lymphocytic Leukaemia 2.2%
Hypertension 2.2%
Stomatitis 1.6%
Aplastic Anaemia 1.2%
Chemotherapy 1.2%
Large Intestine Carcinoma 1.2%
Prophylaxis Against Graft Versus Host Disease 1.2%
Systemic Mycosis 1.2%
Colon Cancer Metastatic 1.0%
Pneumonia 1.0%
Rectal Cancer 1.0%
Osteitis 18.9%
Renal Impairment 9.4%
Hypogammaglobulinaemia 7.5%
Liver Disorder 7.5%
Sepsis 5.7%
Septic Shock 5.7%
Vomiting 5.7%
Gastric Ulcer 3.8%
Herpes Zoster 3.8%
Hyponatraemia 3.8%
Myocardial Ischaemia 3.8%
Osteomyelitis 3.8%
Pulmonary Artery Thrombosis 3.8%
Pyrexia 3.8%
Thrombocytopenia 3.8%
Convulsion 1.9%
Depression 1.9%
Diabetic Ketoacidosis 1.9%
Drug Hypersensitivity 1.9%
Duodenal Ulcer Perforation 1.9%
Concomitant
Prophylaxis 22.2%
Product Used For Unknown Indication 14.6%
Neoplasm Malignant 11.2%
Premedication 8.9%
Colon Cancer 4.7%
Multiple Myeloma 4.6%
Colorectal Cancer 3.6%
Constipation 3.3%
Hypertension 3.3%
Prophylaxis Of Nausea And Vomiting 3.1%
Drug Use For Unknown Indication 3.0%
Cancer Pain 2.6%
Adenocarcinoma Pancreas 2.4%
Rectal Cancer 2.4%
Psoriasis 1.8%
Breast Cancer 1.8%
Colon Cancer Metastatic 1.8%
Breast Cancer Recurrent 1.7%
Lung Adenocarcinoma 1.5%
Ovarian Cancer Recurrent 1.5%
White Blood Cell Count Decreased 24.3%
Stomatitis 8.9%
Vomiting 7.8%
Interstitial Lung Disease 6.5%
Osteitis 4.9%
Rash 4.3%
Pneumonia 4.0%
Renal Failure Acute 4.0%
Thrombocytopenia 4.0%
Sepsis 3.8%
Oedema Peripheral 3.5%
Ovarian Cancer 3.5%
Renal Impairment 3.5%
Neutrophil Count Decreased 2.7%
Pyrexia 2.7%
White Blood Cell Count Increased 2.7%
Nausea 2.4%
Therapeutic Response Decreased 2.4%
Rectal Ulcer 2.2%
Palmar-plantar Erythrodysaesthesia Syndrome 1.9%

Drug Data